Paritaprevir

CAS No. 1216941-48-8

Paritaprevir( ABT-450 | Veruprevir )

Catalog No. M10813 CAS No. 1216941-48-8

Paritaprevir (ABT-450, Veruprevir) is a potent HCV NS3/4A protease inhibitor with EC50 of 1 and 0.21 nM for HCV GT 1a and 1b, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 79 Get Quote
5MG 132 Get Quote
10MG 168 Get Quote
25MG 302 Get Quote
50MG 492 Get Quote
100MG 710 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Paritaprevir
  • Note
    Research use only, not for human use.
  • Brief Description
    Paritaprevir (ABT-450, Veruprevir) is a potent HCV NS3/4A protease inhibitor with EC50 of 1 and 0.21 nM for HCV GT 1a and 1b, respectively.
  • Description
    Paritaprevir (ABT-450, Veruprevir) is a potent HCV NS3/4A protease inhibitor with EC50 of 1 and 0.21 nM for HCV GT 1a and 1b, respectively; demonstrates in vitro antiviral activity against HCV GT1-4 and GT6 (EC50=0.09 to 19 nM), and an EC50 of 0.09 nM against GT4a; The combination of paritaprevir, ritonavir, ombitasvir (an NS5A protein inhibitor), and dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections.HCV Infection Approved.
  • In Vitro
    Paritaprevir has in vitro antiviral activity against HCV GT1-4 and GT6 (EC50 range, 0.09 to 19 nM), with an EC50 of 0.09 nM against GT4a.
  • In Vivo
    The combination of Paritaprevir, Ritonavir, Ombitasvir (an NS5A protein inhibitor), and Dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections.The acute toxicity of Paritaprevir is considered to be low. Single oral doses of ≤600 mg/kg in rats and ≤100 mg/kg in dogs produces no mortality and were well tolerated. However, since Paritaprevir is administered without ritonavir as a PK enhancer, the exposures are low, especially in male rats (rat 600 mg/kg, males: Cmax 1.82 μg/mL, AUC0-24 8.89 μg·h/mL; dog 100 mg/kg, mean: Cmax 61.3 μg/mL, AUC0-24 285 μg·h/mL).
  • Synonyms
    ABT-450 | Veruprevir
  • Pathway
    Microbiology/Virology
  • Target
    HCV
  • Recptor
    HCV
  • Research Area
    Infection
  • Indication
    HCV Infection

Chemical Information

  • CAS Number
    1216941-48-8
  • Formula Weight
    765.8771
  • Molecular Formula
    C40H43N7O7S
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=C([C@]([C@]1([H])/C=C\CCCCC[C@@H]2NC(C3=NC=C(C)N=C3)=O)(C1)NC([C@@](C[C@@H](OC4=C5C=CC=CC5=C(C=CC=C6)C6=N4)C7)([H])N7C2=O)=O)NS(=O)(C8CC8)=O
  • Chemical Name
    Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2R,6S,12Z,13aS,14aR,16a

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Schnell G, et al. Antimicrob Agents Chemother. 2015 Nov;59(11):6807-15. 2. Carrion AF, et al. Expert Opin Pharmacother. 2014 Apr;15(5):711-6. 3. Zeuzem S, et al. N Engl J Med. 2014 Apr 24;370(17):1604-14. 4. Andreone P, et al. Gastroenterology. 2014 Aug;147(2):359-365.e1.
molnova catalog
related products
  • Tegobuvir

    A nonnucleoside inhibitor of HCV NS5B polymerase that acts as a potent inhibitor of HCV genotype 1.

  • Daclatasvir

    A potent HCV NS5A inhibitor with EC50 of <50 pM against genotype 1 replicons.

  • Beta-d-N4-hydroxycyt...

    Beta-d-N4-hydroxycytidine (NHC) is a nucleoside analogue that has antipestivirus and antihepacivirus activities.